Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Biberach – page 24

668 clinical trials in Biberach, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Biberach at a glance
668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

668 trials in Biberach

Open in trial search

Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Biberach

What the registry says about research in the country

01 Eye Diseases and Related Research

In Biberach An Der Riss, much of the clinical trial activity is connected to eye diseases and broader investigational research in healthy volunteers. The studies are focused on understanding how new treatments are absorbed, how food affects them, and how they interact with other medicines.

  • Research involving Eye Diseases and unspecified disease areas
  • Studies in healthy volunteers and otherwise healthy participants
  • Trials exploring pharmacokinetics and medicine interactions
  • Work aimed at improving treatment use and safety for future care

These trials help clarify how candidate therapies behave in the body and support the development of better treatment options.

02 Pharmacokinetic Studies

A major part of the research landscape centers on pharmacokinetic trial work, especially in healthy people. These studies are designed to see how medicines are absorbed, distributed, and influenced by food or other drugs.

  • Testing how different formulations are taken up in the body
  • Checking the effect of food on medicine exposure
  • Evaluating possible drug-drug interactions
  • Supporting the safe development of new oral therapies

The goal is to build a clearer picture of how investigational medicines behave before wider clinical use.

03 Healthy Volunteer Trials

Many of the studies in this city involve healthy volunteer trial designs, which are used to test safety, tolerability, and how the body responds to new compounds. This research is essential for early evaluation of promising medicines.

  • Assessing how well new treatments are tolerated
  • Comparing tablet and injection-style formulations
  • Measuring exposure changes with common co-medications
  • Generating data that supports further clinical development

The emphasis is on careful observation of how healthy participants respond to study medicines.

04 Metabolic and Cardiovascular Research

Some trials also address broader metabolic and cardiovascular interests, including medicines studied for body weight-related conditions and heart effects. These projects aim to understand both benefit and safety across different formulations.

  • Research on therapies related to obesity and metabolism
  • Studies of heart-related effects and medicine exposure
  • Comparisons of separate versus combined medicine use
  • Support for better treatment planning in chronic disease care

This area reflects a wider effort to refine new treatments for complex health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.